Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Ani Pharmaceuticals (ANIP) Operating Margin: 2012-2025

Historic Operating Margin for Ani Pharmaceuticals (ANIP) over the last 14 years, with Sep 2025 value amounting to 15.91%.

  • Ani Pharmaceuticals' Operating Margin rose 2974.00% to 15.91% in Q3 2025 from the same period last year, while for Sep 2025 it was 8.70%, marking a year-over-year increase of 660.00%. This contributed to the annual value of 0.10% for FY2024, which is 955.00% down from last year.
  • Ani Pharmaceuticals' Operating Margin amounted to 15.91% in Q3 2025, which was up 142.04% from 6.57% recorded in Q2 2025.
  • In the past 5 years, Ani Pharmaceuticals' Operating Margin ranged from a high of 27.19% in Q1 2021 and a low of -38.94% during Q4 2021.
  • In the last 3 years, Ani Pharmaceuticals' Operating Margin had a median value of 9.27% in 2023 and averaged 6.98%.
  • As far as peak fluctuations go, Ani Pharmaceuticals' Operating Margin surged by 4,294bps in 2021, and later slumped by 5,696bps in 2022.
  • Ani Pharmaceuticals' Operating Margin (Quarterly) stood at -38.94% in 2021, then spiked by 4,087bps to 1.93% in 2022, then soared by 318bps to 5.11% in 2023, then slumped by 741bps to -2.30% in 2024, then surged by 2,974bps to 15.91% in 2025.
  • Its last three reported values are 15.91% in Q3 2025, 6.57% for Q2 2025, and 13.29% during Q1 2025.